Document is current
Any future updates will be listed below
-
Authors
Patchsung, Maturada
Jantarug, Krittapas
Pattama, Archiraya
Aphicho, Kanokpol
Suraritdechachai, Surased
Meesawat, Piyachat
Sappakhaw, Khomkrit
Leelahakorn, Nattawat
Ruenkam, Theerawat
Wongsatit, Thanakrit
Athipanyasilp, Niracha
Eiamthong, Bhumrapee
Lakkanasirorat, Benya
Phoodokmai, Thitima
Niljianskul, Nootaree
Pakotiprapha, Danaya https://orcid.org/0000-0002-5017-8283
Chanarat, Sittinan
Homchan, Aimorn https://orcid.org/0000-0002-1528-2915
Tinikul, Ruchanok
Kamutira, Philaiwarong
Phiwkaow, Kochakorn
Soithongcharoen, Sahachat
Kantiwiriyawanitch, Chadaporn
Pongsupasa, Vinutsada
Trisrivirat, Duangthip
Jaroensuk, Juthamas
Wongnate, Thanyaporn
Maenpuen, Somchart
Chaiyen, Pimchai
Kamnerdnakta, Sirichai
Swangsri, Jirawat
Chuthapisith, Suebwong
Sirivatanauksorn, Yongyut
Chaimayo, Chutikarn
Sutthent, Ruengpung
Kantakamalakul, Wannee
Joung, Julia https://orcid.org/0000-0001-6656-5002
Ladha, Alim
Jin, Xin
Gootenberg, Jonathan S. https://orcid.org/0000-0003-2757-2175
Abudayyeh, Omar O.
Zhang, Feng
Horthongkham, Navin https://orcid.org/0000-0001-9109-1259
Uttamapinant, Chayasith https://orcid.org/0000-0003-0114-0577
-
Funding
Funding for this research was provided by:
The project is financially supported by PTT, PTTEP, Kasikorn Bank, Siam Commercial Bank, GPSC, VISTEC, and Siriraj Hospital.
- License Information
-
More Information
Article History
Received: 15 June 2020
Accepted: 24 July 2020
First Online: 26 August 2020
Competing interests
: O.O.A., J.S.G. and F.Z. are co-founders and scientific advisors for and hold equity interests in Sherlock Biosciences, Inc. F.Z. is also a co-founder of Editas Medicine, Beam Therapeutics, Pairwise Plants and Arbor Biotechnologies. C.U., S. Suraritdechachai, K.A., N.L., T. Wongsatit, M.P., K.J., P.M., K.S. and T.R. are inventors on a patent application (Thai patent application no. 2001004005) related to lateral-flow detection of nuclease activity filed by VISTEC. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.
